ディスレクシア治療の世界市場

ディスレクシア治療の世界市場は2030年までに95億米ドルに達する見込み

2024年に74億米ドルと推定されるディスレクシア治療の世界市場は、2024年から2030年にかけてCAGR 4.3％で成長し、2030年には95億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである音韻ディスレクシア治療は、CAGR 3.9%を記録し、分析期間終了時には47億米ドルに達すると予測されます。サーフェスディスレクシア治療分野の成長率は、分析期間中CAGR 3.7%と推定されます。

米国市場は20億米ドル、中国はCAGR 6.8％で成長予測

米国のディスレクシア治療市場は、2024年に20億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と4.3%と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界のディスレクシア治療市場- 主要動向と促進要因のまとめ

ディスレクシアの診断と管理への世界の注目の原動力は？

ディスレクシアは、読解、綴り、言語処理の困難を特徴とする神経学的学習障害であり、世界人口の約5～15％が罹患しています。神経発達障害とその長期的な学業的・社会的影響に対する認識の高まりにより、早期診断と効果的な介入戦略への投資が増加しています。北米、欧州、アジア太平洋の教育システムでは、小学校の段階でディスレクシアのスクリーニングを統合し、タイムリーな治療と適応計画を促進しています。

不安、低い自尊心、退学リスクなど、ディスレクシアの心理的負担は、ヘルスケアシステムに教育と心理的支援の枠組みを統合するよう促しています。早期介入は識字能力と社会的転帰を大幅に改善することが示されており、エビデンスに基づく治療と支援技術への需要を煽っています。

ディスレクシア治療モダリティを再構築するイノベーションとは？

技術の進歩は、ディスレクシアの治療と管理方法を変えつつあります。デジタル学習プラットフォーム、AIを搭載したフォニックスアプリ、ゲーム化された読み書きツールは、子供の学習ペースに適応した個別化治療を可能にしています。ウェアラブルニューロフィードバックデバイスや言語療法との統合も、読書練習中の認知的関与の改善に役立っています。

これと並行して、神経科医、教育者、心理学者を含む学際的なアプローチが主流になりつつあります。fMRIやEEGのようなツールは、ディスレクシアの神経学的基礎を研究するために使用されており、脳に基づく介入の開発を導いています。薬物による治療はまだ実験段階であるが、向精神薬や神経刺激薬の可能性を探る製薬研究も行われています。

治療アクセスはどこで拡大・発展しているのか？

世界の教育改革、特に高所得国では、ディスレクシアにやさしいカリキュラム、教員研修、学習補助の法的義務化がますます進んでいます。開発途上地域は、NGO主導の識字率向上キャンペーンや、十分な教育を受けていないコミュニティを対象としたモバイル教育プラットフォームを通じて、これに追随し始めています。

セラピーのプロバイダーは、遠隔地の子どもたちにも対応できるよう、対面セッションと遠隔セラピーを組み合わせたハイブリッドモデルを提供しています。民間セクターは専門的な学習センターやEdtechソリューションに投資しており、一部の地域では保険会社が学習障害に対する心理学的評価やセラピー・セッションの払い戻しを始めています。

市場成長と治療イノベーションの原動力は？

ディスレクシア治療市場の成長は、診断インフラの拡大、インクルーシブ教育に対する需要の高まり、デジタル治療ツールの普及など、いくつかの要因によってもたらされます。特に欧州と北米では、早期介入に対する政府の義務化が、評価と支援サービスに対する旺盛な需要を生み出しています。

テクノロジー・プロバイダーは、拡張可能でエビデンスの裏付けがあるAI主導の個別指導や脳トレ・アプリに投資しています。一方、保護者の意識の高まりと擁護運動は、普遍的なスクリーニングと適応基準を採用するよう学校システムに圧力をかけています。これらの力は、教育および臨床の両領域で継続的な拡大が見込まれるダイナミックな市場を形成しています。

セグメント

タイプ（音韻性ディスレクシア、表層性ディスレクシア、二重欠損ディスレクシア、その他のタイプ）、薬剤クラス（抗ヒスタミン薬、中枢神経刺激薬、選択的ノルエピネフリン再取り込み阻害薬、その他の薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の合計42社）

• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• ANI Pharmaceuticals Inc.
• AstraZeneca PLC
• Bionpharma Inc.
• Breckenridge Pharmaceutical Inc.
• DK Pharmachem Pvt Ltd.
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• GSK plc
• Ironshore Pharmaceuticals Inc.
• Jubilant Pharma Limited
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Dyslexia Treatment Market to Reach US$9.5 Billion by 2030

The global market for Dyslexia Treatment estimated at US$7.4 Billion in the year 2024, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Phonological Dyslexia Treatment, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Surface Dyslexia Treatment segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 6.8% CAGR

The Dyslexia Treatment market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Dyslexia Treatment Market - Key Trends & Drivers Summarized

What Is Driving the Global Focus on Dyslexia Diagnosis and Management?

Dyslexia, a neurological learning disorder characterized by difficulties in reading, spelling, and language processing, affects approximately 5-15% of the global population. Growing awareness of neurodevelopmental disorders and their long-term academic and social impact has led to earlier diagnosis and increased investment in effective intervention strategies. Educational systems in North America, Europe, and Asia-Pacific are integrating dyslexia screening at primary school levels, facilitating timely treatment and accommodation plans.

The psychological burden of dyslexia-including anxiety, low self-esteem, and dropout risk-is prompting healthcare systems to integrate educational and psychological support frameworks. Early intervention has been shown to significantly improve literacy and social outcomes, fueling demand for evidence-based therapies and assistive technologies.

What Innovations Are Reshaping Dyslexia Treatment Modalities?

Technological advancements are transforming how dyslexia is treated and managed. Digital learning platforms, AI-powered phonics apps, and gamified literacy tools are enabling personalized therapy that adapts to a child’s learning pace. Wearable neurofeedback devices and speech therapy integrations are also helping improve cognitive engagement during reading exercises.

In parallel, multidisciplinary approaches involving neurologists, educators, and psychologists are becoming the norm. Tools like fMRI and EEG are being used to study the neurological basis of dyslexia, guiding the development of brain-based interventions. Pharmaceutical research is exploring the potential of nootropics and neurostimulants, though drug-based treatment remains in experimental stages.

Where Is Treatment Access Expanding and Evolving?

Global education reforms, particularly in high-income nations, are increasingly including dyslexia-friendly curricula, teacher training, and legal mandates for learning accommodations. Developing regions are beginning to follow suit through NGO-driven literacy campaigns and mobile education platforms targeting underserved communities.

Therapy providers are offering hybrid models, combining in-person sessions with teletherapy to reach children in remote areas. The private sector is investing in specialized learning centers and edtech solutions, while insurance providers in select regions are starting to reimburse psychological assessments and therapy sessions for learning disabilities.

What Is Driving Market Growth and Therapeutic Innovation?

The growth in the dyslexia treatment market is driven by several factors including expanding diagnostic infrastructure, rising demand for inclusive education, and the proliferation of digital therapeutic tools. Government mandates for early intervention, especially in Europe and North America, are creating robust demand for assessment and support services.

Technology providers are investing in AI-driven tutoring and brain-training apps that are scalable and evidence-backed. Meanwhile, growing parental awareness and advocacy movements are pressuring school systems to adopt universal screening and accommodation standards. These forces are jointly shaping a dynamic market that is expected to see continued expansion in both educational and clinical domains.

SCOPE OF STUDY:

The report analyzes the Dyslexia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia, Other Types); Drug Class (Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• ANI Pharmaceuticals Inc.
• AstraZeneca PLC
• Bionpharma Inc.
• Breckenridge Pharmaceutical Inc.
• DK Pharmachem Pvt Ltd.
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• GSK plc
• Ironshore Pharmaceuticals Inc.
• Jubilant Pharma Limited
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Dyslexia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Early Diagnosis Rates Drive Demand for Evidence-Based Interventions in Dyslexia Treatment
  • Advances in Neuroscience Propel Development of Targeted Cognitive and Language Processing Therapies
  • Integration of Gamified Learning Platforms Enhances Engagement in Dyslexia Education Programs
  • Use of AI and Machine Learning Algorithms Improves Personalization of Reading Intervention Tools
  • Public Policy Reforms in Education Support Increased Access to Dyslexia Screening and Treatment
  • Adoption of Multisensory Teaching Approaches Gains Traction Across School Systems Globally
  • Growth in Online Learning Platforms Creates Opportunities for Digital Dyslexia Therapy Solutions
  • Rising Parental Awareness and Advocacy Spurs Demand for Early Intervention Programs
  • Neuroplasticity Research Enhances Scientific Understanding of Dyslexia Remediation Pathways
  • Voice and Speech Recognition Technologies Improve Accessibility in Digital Reading Aids
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dyslexia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dyslexia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dyslexia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Dyslexia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Phonological Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Phonological Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Phonological Dyslexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Surface Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Surface Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Surface Dyslexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Double Deficit Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Double Deficit Dyslexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Double Deficit Dyslexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Central Nervous Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Central Nervous Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Central Nervous Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Selective Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Selective Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Selective Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• JAPAN
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• CHINA
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• EUROPE
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Dyslexia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Dyslexia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• FRANCE
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• GERMANY
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Dyslexia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• INDIA
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Dyslexia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Dyslexia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Dyslexia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Dyslexia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
• AFRICA
  • Dyslexia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Dyslexia Treatment by Type - Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Dyslexia Treatment by Type - Percentage Breakdown of Value Sales for Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia and Other Types for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Dyslexia Treatment by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Dyslexia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Dyslexia Treatment by Drug Class - Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Dyslexia Treatment by Drug Class - Percentage Breakdown of Value Sales for Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030

IV. COMPETITION